Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.

International journal of cancer·2026
Same author

Symptom distress evolution over the first year after allogeneic stem cell transplantation - a prospective observational sub-study of the SMILe project.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Author Correction: Age-related epithelial defects limit thymic function and regeneration.

Nature immunology·2026
Same author

Immune-mediated side effects of cancer immunotherapies.

Blood·2026
Same author

Chronic graft-versus-host disease: Current situation and unmet needs - A European position statement.

Bone marrow transplantation·2026
Same author

Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.

Haematologica·2026
Same journal

Transplanted Cerebrospinal Fluid-Contacting Neurons Alleviate Spasticity Following Spinal Cord Injury in Mice.

Current stem cell research & therapy·2026
Same journal

Ear Cartilage Reconstruction: From Regenerative Medicine to Reconstructive Surgery.

Current stem cell research & therapy·2026
Same journal

Application of Wharton's Jelly Derived from Human Umbilical Cord in Tissue Engineering.

Current stem cell research & therapy·2026
Same journal

Gestational Age, Maternal Age, and Culture Dynamics Shape the Pluripotency Marker Profile of Primary Amniocytes: Insights for Stem Cell Biology and Regenerative Applications.

Current stem cell research & therapy·2026
Same journal

Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Cell Therapy in Hematological Malignancies - A Systematic Review and Meta Analysis.

Current stem cell research & therapy·2026
Same journal

Preface.

Current stem cell research & therapy·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Immunotherapy for malignant melanoma.

Robert Zeiser1, Marc Schnitzler, Hana Andrlova

  • 1Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwigs University, Freiburg, Germany. robert.zeiser@uniklinik-freiburg.de

Current Stem Cell Research & Therapy
|February 15, 2012
PubMed
Summary
This summary is machine-generated.

Ipilimumab, an antibody targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), shows promise in treating metastatic melanoma. This immunotherapy approach offers encouraging clinical activity despite manageable, mechanism-related toxicities.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Experiment Videos

Last Updated: May 25, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Area of Science:

  • Immunology
  • Oncology
  • Dermatology

Background:

  • Metastatic melanoma treatment remains challenging, with limited success in improving patient survival via conventional agents.
  • Previous immunotherapies like cytokine therapy and vaccination have yielded unsatisfactory responses in melanoma.
  • Melanoma's immunogenicity prompted research into immune-mediated rejection mechanisms.

Purpose of the Study:

  • To review past immunotherapeutical approaches for melanoma.
  • To focus on cytotoxic T-lymphocyte antigen-4 (CTLA-4) blockade as a novel treatment strategy.
  • To analyze the mechanism, clinical efficacy, and immunological side effects of CTLA-4 blockade.

Main Methods:

  • Review of existing literature on melanoma immunotherapies.
  • Focus on the development and clinical application of anti-CTLA-4 antibodies.
  • Analysis of preclinical data from rodent models and clinical trial outcomes.

Main Results:

  • Development of ipilimumab, an antibody targeting CTLA-4, a key negative regulator of T-cell response.
  • Encouraging activity observed in advanced melanoma patients treated with ipilimumab, with unique response patterns.
  • Acute toxicities associated with ipilimumab were severe and mechanism-related but generally manageable and reversible.

Conclusions:

  • CTLA-4 blockade represents a significant advancement in melanoma immunotherapy.
  • Ipilimumab demonstrates clinical effectiveness in advanced melanoma, warranting further investigation.
  • Understanding and managing the immunological side effects are crucial for successful CTLA-4 blockade therapy.